Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Target Lowered at Citigroup

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price objective decreased by Citigroup from $32.00 to $22.00 in a research report sent to investors on Thursday morning,Benzinga reports. Citigroup currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts have also recently issued reports on the stock. Robert W. Baird cut shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $40.00 to $16.00 in a research note on Thursday, September 3rd. Guggenheim cut their price objective on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th. HC Wainwright decreased their target price on Ultragenyx Pharmaceutical from $50.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, September 3rd. Wall Street Zen raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, October 6th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $29.79.

Ultragenyx Pharmaceutical Stock Down 9.3%

Shares of Ultragenyx Pharmaceutical stock opened at $15.57 on Thursday. Ultragenyx Pharmaceutical has a 12-month low of $12.73 and a 12-month high of $39.89. The stock’s fifty day moving average is $16.24 and its 200-day moving average is $22.75.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.06). The company had revenue of $173.00 million for the quarter, compared to analysts’ expectations of $182.49 million. During the same period last year, the company earned ($1.81) earnings per share. The business’s revenue for the quarter was up 8.2% on a year-over-year basis. As a group, sell-side analysts predict that Ultragenyx Pharmaceutical will post -4.30 EPS for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,066 shares of the business’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $15.27, for a total transaction of $107,897.82. Following the completion of the sale, the chief financial officer directly owned 89,229 shares of the company’s stock, valued at approximately $1,362,526.83. The trade was a 7.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 8,510 shares of company stock valued at $127,561. 5.20% of the stock is currently owned by company insiders.

Institutional Trading of Ultragenyx Pharmaceutical

Several hedge funds have recently added to or reduced their stakes in the business. Jefferies Financial Group Inc. lifted its stake in Ultragenyx Pharmaceutical by 44.1% in the third quarter. Jefferies Financial Group Inc. now owns 1,339,814 shares of the biopharmaceutical company’s stock valued at $20,137,000 after buying an additional 410,188 shares in the last quarter. Fulcrum Asset Management LLP increased its position in shares of Ultragenyx Pharmaceutical by 4,543.8% in the third quarter. Fulcrum Asset Management LLP now owns 5,201 shares of the biopharmaceutical company’s stock valued at $80,000 after acquiring an additional 5,089 shares during the last quarter. Commonwealth Equity Services LLC bought a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $661,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Ultragenyx Pharmaceutical in the third quarter valued at $76,000. Finally, Profund Advisors LLC grew its holdings in Ultragenyx Pharmaceutical by 49.4% during the third quarter. Profund Advisors LLC now owns 76,847 shares of the biopharmaceutical company’s stock worth $1,155,000 after purchasing an additional 25,397 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Key Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Some analysts raised targets: TD Cowen lifted its target to $19 and Morgan Stanley to $22; both maintained their existing ratings. TD Cowen analyst recommendations
• Neutral Sentiment: Ultragenyx reaffirmed its 2026 and 2027 earnings guidance, offering some continuity, though this did not offset the weaker quarterly results and lower analyst targets. Guidance update
• Negative Sentiment: Q3 revenue of $173 million and adjusted EPS of negative $1.16 fell short of analyst expectations of $182.5 million and negative $1.10, respectively. Revenue nevertheless grew 8.2% year over year. Q3 results
• Negative Sentiment: Citigroup cut its target from $32 to $22 and Barclays from $35 to $32, despite retaining Buy and Overweight ratings. Canaccord also lowered its target from $39 to $34. These reductions signal more cautious expectations even though the targets remain above the current share price. Citigroup analyst recommendations
• Negative Sentiment: Goldman Sachs and Wedbush also cut targets, to $17 and $22, respectively, maintaining Neutral ratings. A Seeking Alpha analysis highlighted dependence on CRYSVITA, limited contribution from newer launches, and profitability plans reliant on R&D cuts—factors that may weigh on confidence in longer-term growth. Ultragenyx analysis

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.